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lAbstract
Background: Recently, 44Sc (T1/2 = 3.97 h, Eβ+av = 632 keV, I = 94.3 %) has emerged
as an attractive radiometal candidate for PET imaging using DOTA-functionalized
biomolecules. The aim of this study was to investigate the potential of using
NODAGA for the coordination of 44Sc. Two pairs of DOTA/NODAGA-derivatized
peptides were investigated in vitro and in vivo and the results obtained with 44Sc
compared with its 68Ga-labeled counterparts.
DOTA-RGD and NODAGA-RGD, as well as DOTA-NOC and NODAGA-NOC, were
labeled with 44Sc and 68Ga, respectively. The radiopeptides were investigated with
regard to their stability in buffer solution and under metal challenge conditions using
Fe3+ and Cu2+. Time-dependent biodistribution studies and PET/CT imaging were
performed in U87MG and AR42J tumor-bearing mice.
Results: Both RGD- and NOC-based peptides with a DOTA chelator were readily
labeled with 44Sc and 68Ga, respectively, and remained stable over at least 4 half-lives
of the corresponding radionuclide. In contrast, the labeling of NODAGA-functionalized
peptides with 44Sc was more challenging and the resulting radiopeptides were clearly
less stable than the DOTA-derivatized matches. 44Sc-NODAGA peptides were clearly
more susceptible to metal challenge than 44Sc-DOTA peptides under the same
conditions. Instability of 68Ga-labeled peptides was only observed if they were
coordinated with a DOTA in the presence of excess Cu2+. Biodistribution data of
the 44Sc-labeled peptides were largely comparable with the data obtained with the
68Ga-labeled counterparts. It was only in the liver tissue that the uptake of 68Ga-labeled
DOTA compounds was markedly higher than for the 44Sc-labeled version and this was
also visible on PET/CT images. The 44Sc-labeled NODAGA-peptides showed a similar
tissue distribution to those of the DOTA peptides without any obvious signs of in vivo
instability.
Conclusions: Although DOTA revealed to be the preferred chelator for stable
coordination of 44Sc, the data presented in this work indicate the possibility of using
NODAGA in combination with 44Sc. In view of a clinical study, thorough investigations
will be necessary regarding the labeling conditions and storage solutions in order to
guarantee sufficient stability of 44Sc-labeled NODAGA compounds.
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44Sc is a novel radiometal which is attractive for positron emission tomography (PET)
imaging, due to the emission of positrons with a high branching ratio (Eβ+av = 632 keV,
I = 94.3 %) (Rösch 2012; Müller et al. 2013). Its physical half-life of 3.97 h enables the
acquisition of PET images several hours after injection of the 44Sc-radiopharmaceuti-
cal and is of particular interest for application with biomolecules, providing slower
kinetic profiles (Chakravarty et al. 2014). Importantly, application of 44Sc would allow
a centralized production of radiopharmaceuticals, followed by transportation to more
remote hospitals (van der Meulen et al. 2015).
44Sc is thought to be useful as a diagnostic match to therapeutic radionuclides
with similar chemical properties, such as 90Y and 177Lu (Müller et al. 2013). Most
interesting, however, would be to use 44Sc in combination with its therapeutic
counterpart 47Sc, which provides excellent β−-decay properties for radionuclide
therapy (Eβ−av = 162 keV, T1/2 = 3.35 d). The potential of
44Sc/47Sc as a theragnostic
pair has been demonstrated recently in a preclinical pilot study with tumor-bearing
mice (Müller et al. 2014).
A crucial requirement for the application of radiopharmaceuticals is the formation
of a thermodynamically stable and kinetically inert complex of the radiometal with a
suitable chelator, which is then linked to the targeting agent (Majkowska-Pilip &
Bilewicz 2011). The coordination of Sc(III) and Ga(III) has previously been investigated
with several macrocyclic polyaminocarboxylic chelators, including 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic
acid (NOTA) (Majkowska-Pilip & Bilewicz 2011; Huclier-Markai et al. 2011; Notni et al.
2012). The studies were performed with natSc(III) stock solutions containing 46Sc as tracer
and the sole chelator without an attached biomolecule. As a result of these investigations,
it was found that Sc(III) forms complexes with both chelators, DOTA and NOTA, how-
ever, the stability of Sc-DOTA was superior to Sc-NOTA complexes (Majkowska-Pilip &
Bilewicz 2011; Huclier-Markai et al. 2011). On the other hand, Ga(III) displays a reverse
behavior, forming more stable complexes with NOTA than with DOTA (Majkowska-Pilip
& Bilewicz 2011; Notni et al. 2012). The DOTA-chelator provides eight coordination sites,
which are all coordinated by Sc(III), whereas NOTA can only form six coordinative bonds.
Due to the higher denticity the Sc-DOTA complex is believed to be thermodynamically
more stable than the Sc-NOTA complex (Huclier-Markai et al. 2011; Port et al. 2008).
Due to the preference of Ga(III) for the coordination number six, all coordination sites of
NOTA are used, while two sites of DOTA remain uncoordinated in a Ga-DOTA-complex
(Majkowska-Pilip & Bilewicz 2011; Viola-Villegas & Doyle 2009).
Despite the reduced stability of a Ga-DOTA complex compared to a Ga-NOTA and
Ga-1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) complex, there are
several examples of 68Ga-DOTA labeled peptides which showed promising in vivo proper-
ties. The 68Ga-labeled somatostatin receptor analogues 68Ga-DOTA-TOC, 68Ga-DOTA-
TATE and 68Ga-DOTA-NOC represent the most prominently applied radiopharmaceuti-
cals in clinical studies for imaging of neuroendocrine tumors (Kwekkeboom et al. 2010).
Recent PET imaging studies in patients using the αvβ3 integrin-targeting radiotracer
68Ga-
NOTA-RGD indicated promising results (Kim et al. 2012; Choi et al. 2013; Yoon et al.
2014). These reports demonstrate that 68Ga is successfully used in clinics with both
DOTA- and NOTA/NODAGA-derivatized targeting agents.
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ies with a range of DOTA-derivatized biomolecules, including bombesin analogues
(Koumarianou et al. 2012), puromycin (Eigner et al. 2013), folate-conjugates (Müller
et al. 2013) and dimeric cyclic RGD peptides (Hernandez et al. 2014). To date, all re-
search with regard to the in vivo and in vitro behavior of 44Sc-labeled radiopharma-
ceuticals was performed with DOTA chelators connected to the respective targeting
agent. The only exception to our knowledge was a study in which an EGFR-targeted
antibody was labeled with 44Sc using a CHX-A-DTPA (N-[(R)-2-amino-3-(para-isothio-
cyanato-phenyl)propyl]trans-(S,S)-cyclohexane-1,2-diamine N,N,N’,N”N”-pentaacetic acid)
chelator (Chakravarty et al. 2014). The question on whether or not a NOTA or NODAGA
chelator would be suited for 44Sc-labeling has remained unclear thus far. Using these che-
lators for coordination of 44Sc would be of interest in combination with radiopharmaceu-
ticals where only the NOTA- or NODAGA-derivatized species are available for clinical
studies, as is the case for NODAGA-RGD: a peptide which is currently employed in clin-
ical trials when labeled with 68Ga. Since application of NODAGA-RGD at later time
points after injection of the radioconjugate would be of interest for nuclear physicians, we
set out to investigate whether 44Sc-labeling with NODAGA-derivatized biomolecules is
possible and whether the in vitro and in vivo behavior of the radiolabeled peptides would
be equal to the DOTA-derivatized matches.
The aim of this study was, therefore, to compare the in vitro and in vivo behavior of
two pairs of peptides with a DOTA- and NODAGA-chelator (Fig. 1), respectively, after
radiolabeling with 44Sc and 68Ga. Cyclic RGD peptides based on the Arg-Gly-Asp se-
quence and NOC, a somatostatin analogue ([Tyr3,1-NaI3]octreotide), were chosen as
targeting agents. The in vitro stability of 44Sc- and 68Ga-labeled DOTA/NODAGA-
RGD and DOTA/NODAGA-NOC was examined in saline in the presence and absence
of competing metal cations. The in vivo behavior was evaluated by the performance of
biodistribution studies and in vivo PET imaging of tumor-bearing mice.Fig. 1 Chemical structures of DOTA-RGD (a), NODAGA-RGD (b), DOTA-NOC (c) and NODAGA-NOC (d)
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Chemicals
44CaCO3, 97.0 % enriched (Trace Sciences International, USA) and graphite powder,
99.9999 % (Alfa Aesar, Germany) were used for target preparation. The N,N,N’,N’-tetra-
n-octyldiglycolamide, non-branched resin (DGA, particle size 50–100 μm, TrisKem
International, France) was used for the separation of Sc(III) from Ca(II). The chemical
separations were performed using MilliQ water (resistance >18 MΩ) and hydrochloric
acid (HCl, 30 % Suprapur, Merck KGaA, Germany). The recycling of the target material
was performed with oxalic acid dihydrate, (Trace SELECT, ≥99.9999 % metals basis,
Fluka Analytical, Germany) and 25 % ammonia solution (Suprapur, Merck KGaA,
Germany).
68Ga was obtained from a 68Ge/68Ga generator IGG100 (Eckert & Ziegler, Berlin,
Germany). The generator was eluted in fractions and the fraction of eluate containing
the highest quantity of 68Ga (approximately 200–250 MBq in 700 μL 0.1 M HCl)
was directly used for radiolabeling purposes without purification. DOTA-RGD
(DOTA-cyclo(RGDfK) acetate, Cat-N° 9863), NODAGA-RGD (NODAGA-RGD tri-
fluoroacetate, Cat-N° 9805), DOTA-NOC (DOTA-NOC acetate, Cat-N° 9712) and
NODAGA-NOC (NODAGA-NOC acetate, Cat-N° 9718) were obtained from ABX
GmbH, advanced biochemical compounds, Germany. Copper chloride dihydrate
was purchased from Merck Millipore, while iron chloride hexahydrate was obtained
from Sigma-Aldrich GmbH. Phosphate buffered saline (PBS) pH 7.4 was prepared
in-house (Additional file 1).Production of 44Sc
44Sc was prepared by proton irradiation of enriched 44Ca targets at the Injector 2 cyclo-
tron at PSI, as previously reported (van der Meulen et al. 2015). The irradiation of targets
with 11 MeV proton beam energy, and a beam current of 50 μA, lasted for 90 min. A col-
umn (1 mL cartridge fitted with 20 μm frit ISOLUTE SPE Accessories, UK) was filled
with 50 – 70 mg DGA extraction chromatographic resin and a second column with 20–
25 mg of the same resin. A 20 μm frit was placed on top of the resin in each column.
DGA columns were preconditioned with 3.0 M HCl. The first step of the separation was
performed as previously reported (van der Meulen et al. 2015). In brief, the target was dis-
solved in 2.5 mL 3.0 M HCl and loaded onto the first DGA column. The rinsing of the
target container and the first DGA column with 3.0 M HCl ensured a complete transfer
of the 44Sc radioactivity and complete removal of residual Ca(II), respectively. 44Sc was
eluted from the first DGA column with 3.5 mL 0.1 M HCl. Subsequently, the solution
was acidified with the addition of 3.3 mL 6.0 M HCl to yield a 3.0 M HCl solution, which
was then passed through the second DGA column, to which the 44Sc activity was sorbed.
The elution of 44Sc from the second column was performed with 700 μL 0.05 M HCl
(pH 1.3) and was used directly for labeling reactions. The radionuclidic purity of
the 44Sc- eluate was quantified by γ-spectrometry using an N-type high-purity
germanium (HPGe) coaxial detector (EURISYS MESURES, France) and the Ortec
InterWinner 7.1 software. The 44Ca-contained waste fraction from the first DGA
column was collected and processed to recover the target material, as described
previously (van der Meulen et al. 2015).
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The total 44Sc and 68Ga activity in the obtained eluate was quantitatively determined
with a dose calibrator (ISOMED 2010, Nuclear–Medizintechnik Dresden GmbH,
Germany) so that the activity required for radiolabeling could be withdrawn. Sodium
acetate solution (0.5 M, pH 8) was added at a ratio of 1:1 to the 44Sc eluate (0.05 M
HCl, pH 0.4–0.6) and at a ratio of 1:2 to the 68Ga generator eluate (0.1 M HCl, pH 1)
to give a pH of 4–4.5. The corresponding peptides (DOTA-RGD, NODAGA-RGD,
DOTA-NOC and NODAGA-NOC, in a 1 mM stock solution) were added to obtain a
specific activity of up to 10 MBq/nmol and the reaction mixture incubated at 95 °C for
10 min. High-performance liquid chromatography (HPLC) with a C-18 reversed–phase
column (XterraTM MS, C18, 5 μm, 150 × 4.6 mm; Waters) was used for quality control.
The mobile phase consisted of MilliQ water containing 0.1 % trifluoracetic acid (A)
and acetonitrile (B) with a gradient of 95 % A and 5 % B to 20 % A and 80 % B over a
period of 15 min at a flow rate of 1.0 mL/min.In vitro stability of 44Sc- and 68Ga-labeled peptides
44Sc- and 68Ga-labeled peptides (radiochemical purity >95 %) were used for the investi-
gation of stability in 0.9 % NaCl. An activity of 80–100 MBq of 44Sc or 68Ga labeling
solution was diluted with 0.9 % NaCl solution to a volume of 800 μL and incubated for
four half-lives of the corresponding radionuclide at 37 °C.
Aliquots were taken from the prepared solutions at different time points over at
least four half-lives, respectively, of 44Sc and 68Ga and analyzed by TLC (TLC was
used, as the high metal concentrations used in this study may impair the long-term
performance of HPLC columns). If initial experiments suggested instability of a com-
pound, aliquots were retrieved more frequently. The TLC plates (Silica-gel 60, Merck)
were developed using 0.1 M sodium citrate (pH 4.7) as mobile phase. The quantitative
distribution of radioactivity was determined with an autoradiography system (Cyclone
Plus, Perkin Elmer) and its associated software (Optiquant, version 5.0). Rf values of 0.2
were observed for 44Sc- and 68Ga-labeled DOTA-RGD and NODAGA-RGD, and of 0.1
for DOTA-NOC and NODAGA-NOC, respectively, whereas for unlabeled 44Sc and 68Ga
a Rf value of 0.9 was calculated.
The influence of high metal cation concentration on the stability of 44Sc and 68Ga
labeled peptides was monitored in solutions containing 0.01 M Fe3+ or Cu2+. An
aqueous metal cation solution (16 μL of a 0.5 M Fe3+/Cu2+ solution) was added to
80–100 MBq of 44Sc or 68Ga labeling solution and diluted with 0.9 % NaCl solution
to a volume of 800 μL. The incubation conditions, time points of retrieving samples
and analysis by TLC were kept the same, as described above.Cell culture
U87MG cells (human glioblastoma cells; ACC® HTB-14TM) and AR42J cells (rat exocrine
pancreatic tumor cells; ACC® CRL1492TM) were purchased from European Collection of
Cell Cultures (ECACC, operated by Public Health England). U87MG cells were grown in
MEM cell culture medium supplemented with 1 % non-essential amino acids (MEM
NEAA solution 100×, Bioconcept), 1 mM sodium pyruvate (Bioconcept), 10 % fetal calf
serum, L-glutamine and antibiotics. AR42J cells were grown in RPMI cell culture medium
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was performed twice a week using trypsin (Gibco by life technologies 0.25 % trypsin-
EDTA) for detachment of the cells.Tumor mouse models
In vivo experiments were approved by the local veterinarian department and conducted
in accordance with the Swiss law of animal protection. Female athymic nude mice
(CD-1 nude), age 5–6 weeks, were obtained from Charles River Laboratories, Sulzfeld,
Germany. U87MG cells and AR42J-cells were suspended in PBS (5 × 106 cells in
100 μL) and subcutaneously inoculated on each shoulder. Two to three weeks later,
when the tumor reached a size of about 300–500 mm3, the mice were used for the
in vivo studies.Biodistribution studies
Biodistribution studies were performed with U87MG tumor and AR42J tumor-bearing
mice 2 weeks after tumor cell inoculation. 44Sc- and 68Ga-labeled peptides (~5 MBq,
~1 nmol per mouse) were intravenously injected in a volume of 100–200 μL. Mice were
sacrificed at 30 min, 2 h and 5 h after injection (p.i.) of the 44Sc-labeled peptides. Mice
which were injected with 68Ga-labeled peptides were sacrificed at 30 min and 2 h p.i.
Selected tissues and organs were collected, weighed, and counted for radioactivity using
a γ-counter (Wallac Wizard 1480, Perkin Elmer). The results were listed as a percent-
age of the injected activity per gram of tissue mass (% IA/g), using counts of a defined
volume of the original injection solution counted at the same time. The data were
analyzed for significance using a two-way ANOVA test (Graph Pad Prism 6 software,
version 6.05). A p-value of < 0.05 was considered statistically significant.Preclinical PET imaging
A bench-top preclinical PET scanner (G8, Sofie Biosciences, California, U.S.A. and Perkin
Elmer, Massachusetts, U.S.A.) was employed for the PET scans of the tumor-bearing mice.
The energy window was set to 150–650 keV. Mice were injected intravenously with
44Sc- or 68Ga-labeled peptides (~10 MBq, ~1 nmol per mouse) in a volume of 100–
200 μL. The PET scans were performed 3 h and 5 h after injection of the 44Sc-labeled pep-
tides and 3 h after injection of the 68Ga-labeled peptides, using G8 acquisition software
(version 2.0.0.10). All static PET scans lasted for 20 min. During the acquisition the mice
were anesthetized by inhalation of a mixture of isoflurane and oxygen. The images were
reconstructed with maximum-likelihood expectation maximization (MLEM). Gauss post-
reconstruction filtering was performed using VivoQuant post-processing software (version
2.10, inviCRO Imaging Services and Software, Boston, U.S.A.).Results
Production and separation of 44Sc
44Sc was quantitatively sorbed on DGA resin in 3.0 M HCl solution, whereas Ca was
not retained. Rinsing the resin with additional 4 mL 3.0 M HCl ensured the complete
removal of Ca, after which 44Sc was eluted with 3.5 mL 0.1 M HCl. The 44Sc eluate
was further acidified with the addition of 6.0 M HCl to yield a 3.0 M HCl solution. The
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~0.3 mL/min, retaining 97 % of the eluted 44Sc activity. 44Sc was eluted quantitatively
(85 ± 2 %), at activities of ~2.0 GBq, with 700 μL 0.05 M HCl and was used directly for
labeling experiments. The separation procedure was initially developed using trace
activities of 46Sc, produced by the 45Sc(n,γ) nuclear reaction at the BR2 reactor at
SCK.CEN, Mol, Belgium.
The 44Sc activity separated from proton irradiated targets containing recycled 44CaCO3
was of the same quality and quantity as using the originally-purchased 44CaCO3 target
material.Radiolabeling and stability of 44Sc- and 68Ga-labeled peptides
Radiolabeling with 44Sc was readily achieved with DOTA-compounds, but found to be
more challenging for NODAGA-compounds, which did not allow reproducible labeling
procedures at high specific activities. Radiolabeling with 68Ga was reproducibly
achieved for both DOTA- and NODAGA-functionalized peptides, however. The radio-
chemical yield of the 44Sc and 68Ga radiosyntheses at the specific activity of 10 MBq/
nmol was >95 %. Quantitative 68Ga-labeling of NODAGA-RGD and NODAGA-NOC
was also possible at room temperature in less than 10 min. TLC and HPLC quality con-
trol were in good agreement. HPLC analysis demonstrated a peak of free 44Sc and 68Ga
at a retention time of 2.2 ± 0.1 min, while the retention times of the radiopeptides were
between 6 and 10 min (Table 1).
The stability of 44Sc- and 68Ga-labeled DOTA- and NODAGA-peptides was first in-
vestigated in 0.9 % NaCl over a period of four half-lives of the corresponding nuclide
by means of TLC. 44Sc- and 68Ga-DOTA-RGD and DOTA-NOC exhibited a high sta-
bility. After four half-lives at 37 °C the amount of intact compound did not decrease
below 98 %. 68Ga-labeled NODAGA-RGD and NODAGA-NOC remained stable, but
the 44Sc-NODAGA peptides became more unstable over time. The amount of intact
44Sc-NODAGA-RGD dropped to 77 % and, in the case of 44Sc-NODAGA-NOC, a
mere 37 % after more than 4 half-lives.
The presence of different metal cations can cause displacement of the radio-
nuclide from the chelator and its release into solution (Pruszynski et al, 2012). The
stability of 44Sc- and 68Ga-labeled DOTA- and NODAGA-peptides was investigated
in the presence of Fe3+ and Cu2+ over four half-lives of the corresponding radio-
nuclide (Fig. 2). The addition of solutions containing these metal cations to result
in final metal concentrations as high as 10 mM did not induce any transmetalation
of 44Sc-labeled DOTA- and 68Ga-labeled NODAGA-compounds. The integrity of
68Ga-DOTA-peptides was not impaired by the presence of Fe3+, however, the
addition of 10 mM Cu2+ reduced the amount of intact 68Ga-DOTA-RGD to 10 %Table 1 HPLC retention times of radiolabeled peptides
Radiopeptide 44Sc-/68Ga-DOTA-RGD 44Sc-/68Ga-NODAGA-RGD
Retention time 6.8 ± 0.1 min 6.1 ± 0.1 min
Radiopeptide 44Sc-/68Ga-DOTA-NOC 44Sc-/68Ga-NODAGA-NOC
Retention time 9.3 ± 0.1 min 9.8 ± 0.1 min
Fig. 2 Stability of 44Sc-DOTA-RGD (a), 44Sc-NODAGA-RGD (b), 68Ga-DOTA-RGD (c), 68Ga-NODAGA-RGD (d),
44Sc-DOTA-NOC (e), 44Sc-NODAGA-NOC (f), 68Ga-DOTA-NOC (g), 68Ga-NODAGA-NOC (h) in saline with and
without the presence of 10 mM Cu2+ and Fe3+, respectively
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both metal cations further destabilized the already less stable 44Sc-labeled
NODAGA-peptides.
Domnanich et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:8 Page 9 of 19Biodistribution studies with 44Sc- and 68Ga-labeled peptides
Biodistribution studies were performed with 44Sc- and 68Ga-labeled DOTA/NODAGA-
RGD and DOTA/NODAGA-NOC in mice bearing U87MG and AR42J tumor xenografts,
respectively (Additional file 1: Table S2-S5).
Time-dependent distribution studies of 44Sc-DOTA-RGD and 44Sc-NODAGA-RGD
revealed a similar pattern for both compounds, resulting in a tumor uptake of 4.88 ±
0.67 % IA/g and 4.50 ± 0.77 % IA/g, respectively, at 0.5 h after injection (Fig. 3a). The
wash-out of radioactivity from the tumor tissue was somewhat faster for the 44Sc-
DOTA-RGD than for the 44Sc-NODAGA-RGD, but at 5 h after injection the values
were almost the same (3.00 ± 0.38 % IA/g vs 3.01 ± 0.55 % IA/g). Clearance from the
blood was fast for both 44Sc-DOTA-RGD and 44Sc-NODAGA-RGD. This was also
reflected by the high renal uptake shortly after injection (4.44 ± 0.51 % IA/g vs 3.89 ±
0.68 % IA/g, 0.5 h p.i.) which decreased with time, resulting in a retention of <2 % IA/g
at 5 h p.i. Whereas the accumulation in non-targeted organs and tissues was generally
comparable, the liver uptake of 44Sc-DOTA-RGD (5.16 ± 0.99 % IA/g, 0.5 h) was clearly
higher than for 44Sc-NODAGA-RGD (1.49 ± 0.06 % IA/g, 0.5 h) at early time points. At
5 h after injection uptake in the liver was ~1 % IA/g for both radiopeptides (Fig. 3a).
The tissue distribution pattern of 44Sc-DOTA-NOC and 44Sc-NODAGA-NOC was
comparable with regard to the uptake in AR42J tumors (9.49 ± 0.76 % IA/g vs. 9.90 ±
0.66 % IA/g), kidneys (12.6 ± 3.36 % IA/g vs. 12.4 ± 1.41 % IA/g) and liver (1.49 ± 0.49 %
IA/g vs. 1.22 ± 0.11 % IA/g) at 0.5 h after injection (Fig. 3b). The tissue distribution
profiles at 2 h after injection of the NOC-based radiopeptides were also comparable. At
5 h after injection, retention of 44Sc-DOTA-NOC in tumors (5.56 ± 0.40 % IA/g) was
lower than for 44Sc-NODAGA-NOC (10.8 ± 0.37 % IA/g), which indicates a faster
wash-out of 44Sc-DOTA-NOC. Renal retention of 44Sc-DOTA-NOC decreased further
over the period of investigation (6.54 ± 0.30 % IA/g, 5 h p.i.) while the accumulation of
activity in the kidneys (13.0 ± 2.98 % IA/g) was increased at 5 h after injection of
44Sc-NODAGA-NOC (Fig. 3b).
For selected organs and tissues, the uptake of the 44Sc-labeled peptides was compared
with the uptake of the 68Ga-labeled peptides in mice at 2 h after injection (Fig. 4). The tis-
sue distribution of DOTA-RGD was almost the same, independent of the radionuclide
(44Sc vs 68Ga) used (Fig. 4a), although the tumor uptake was higher for 44Sc-DOTA-RGD
(2.99 ± 0.16 % IA/g) than for 68Ga-DOTA-RGD (2.35 ± 0.27 % IA/g, p <0.05). The
NODAGA-derivatized RGD-peptides revealed the same trend: the tumor uptake of
44Sc-NODAGA-RGD (4.05 ± 0.89 IA/g) was significantly higher (p <0.05) than the
tumor uptake of 68Ga-NODAGA-RGD (3.13 ± 0.27 % IA/g). Undesired accumulation of
44Sc-NODAGA-RGD in the liver (1.34 ± 0.27 % IA/g, p <0.05) was significantly reduced
compared to 68Ga-NODAGA-RGD (2.09 ± 0.08 % IA/g, Fig. 4b). Renal uptake of 44Sc-
NODAGA-RGD was also slightly lower than for 68Ga-NODAGA-RGD. The DOTA-RGD
accumulated to a higher extent in the liver than the NODAGA-RGD, irrespective of
which radionuclide was used for labeling (Fig. 4a/b). In all other organs of interest, the
distribution profile was roughly the same, irrespective of the chelator used for coordin-
ation of the radionuclide.
Accumulation of 44Sc-DOTA-NOC in the tumor xenografts (8.83 ± 0.57 % IA/g) was
significantly lower (p <0.05) when compared to the uptake of 68Ga-DOTA-NOC (12.2 ±
2.29 % IA/g) (Fig. 4c). This was also the case in the liver, where the uptake of 44Sc-DOTA-
Fig. 3 Biodistribution data obtained at different time points after injection of ~5 MBq (1 nmol) 44Sc-DOTA/NODAGA-
RGD in U87MG tumor-bearing mice (a) and after injection of ~5 MBq (1 nmol) 44Sc-DOTA/NODAGA-NOC in AR42J
tumor-bearing mice (b), respectively. Data bars represent the average ± SD of values obtained from n= 3 mice
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(5.52 ± 0.88 % IA/g). In all other organs and tissues the distribution of radioactivity was
comparable among the radiopeptides, irrespective of whether they were labeled with 44Sc
or 68Ga (Fig. 4c). The tissue distribution of 44Sc-NODAGA-NOC and 68Ga-NODAGA-
NOC was also comparable (Fig. 4d). The only significant difference (p <0.05) were the
kidneys, in which 44Sc-NODAGA-NOC was less retained (8.64 ± 1.62 % IA/g) than the
68Ga-NODAGA-NOC (11.5 ± 1.15 % IA/g). The liver uptake of 44Sc-NODAGA-NOC
(0.88 ± 0.15 % IA/g) was lower than for 68Ga-NODAGA-NOC (1.68 ± 0.19 % IA/g) but
the difference was not significant (Fig. 4c). Comparison of the DOTA-NOC and
NODAGA-NOC revealed similar distribution profiles, irrespective of the radionuclide
employed. As the only exception, it should be mentioned that 68Ga-DOTA-NOC showed
a clearly higher retention in the liver than all other NOC-based radiopeptides (Fig. 4c/d).
As a result of the tissue distribution data reported above, the tumor-to-background
ratios were mostly similar between 44Sc-labeled DOTA-RGD and NODAGA-RGD as
Fig. 4 Biodistribution data obtained 2 h after injection of ~5 MBq (~1 nmol) 44Sc- and 68Ga-labeled DOTA-RGD
(a) and NODAGA-RGD (b) and ~5 MBq (~1 nmol) DOTA-NOC (c) and NODAGA-NOC (d). Data bars represent
the average ± SD of values obtained from n = 3 mice (* significantly different uptake of the 44Sc-labeled peptide
compared to the 68Ga-labeled peptide, p <0.05)
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and 3). When comparing variation of tumor-to-background ratios between the 44Sc-
and 68Ga-labeled versions of each of the four peptides, the ratios appeared more pro-
nounced for the NOC-based radiopeptides over their RGD-based counterparts (Tables 2
and 3).Preclinical PET imaging studies with 44Sc- and 68Ga-labeled peptides
PET/CT experiments were performed with one or two mice 3 h after injection of 44Sc-
and 68Ga-labeled DOTA-RGD, NODAGA-RGD, DOTA-NOC and NODAGA-NOC,
respectively (Figs. 5 and 6). 44Sc-DOTA-RGD showed clearly less accumulation of
radioactivity in the liver than 68Ga-DOTA-RGD (Fig. 5a/b). 44Sc-NODAGA-RGD was
comparable to 68Ga-NODAGA-RGD but showed somewhat more background activity
in the abdominal tract (Fig. 5c/d). The uptake pattern of 44Sc-DOTA-RGD was slightly
more favorable over the distribution of 44Sc-NODAGA-RGD (Fig. 5a/c).
PET/CT scans obtained at 3 h after injection of 44Sc-DOTA-NOC revealed uptake of
radioactivity only in the tumor xenografts and in the kidneys, while 68Ga-DOTA-NOC
accumulated also to a significant extent in the liver (Fig. 6a/b). 44Sc-NODAGA-NOC
and 68Ga-NODAGA-NOC accumulated solely in tumors and kidneys (Fig. 6c/d). The
Table 2 Tumor-to-background ratios at different time points after injection of 44Sc/68Ga-labeled
DOTA-RGD and NODAGA-RGD
44Sc-DOTA-RGD 68Ga-DOTA-RGD
U87MG 30 min p.i. 2 h p.i. 5 h p.i. 30 min p.i. 2 h p.i.
Tumor-to-blood 4.82 ± 1.60 40.1 ± 15.6 47.2 ± 18.0 4.34 ± 0.57 28.0 ± 4.26
Tumor-to-liver 0.99 ± 0.14 0.61 ± 0.04 2.90 ± 0.38 0.55 ± 0.09 0.48 ± 0.07
Tumor-to-kidney 1.16 ± 0.29 1.77 ± 0.13 1.82 ± 0.21 0.88 ± 0.07 1.74 ± 0.19
44Sc-NODAGA-RGD 68Ga-NODAGA-RGD
U87MG 30 min p.i. 2 h p.i. 5 h p.i. 30 min p.i. 2 h p.i.
Tumor-to-blood 4.73 ± 1.24 34.1 ± 7.62 30.5 ± 9.93 4.17 ± 0.47 114 ± 35.0
Tumor-to-liver 3.02 ± 0.40 3.01 ± 0.13 2.82 ± 0.21 1.72 ± 0.16 1.50 ± 0.20
Tumor-to-kidney 1.18 ± 0.28 2.68 ± 0.14 2.58 ± 0.24 0.89 ± 0.03 1.49 ± 0.21
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was reduced, resulting in lower tumor-to-kidney ratios compared to 68Ga-NODAGA-
NOC. In this context, it has to be mentioned that 44Sc-NODAGA-NOC was prepared
at a low specific activity for the PET scan (Fig. 6c) which implies that the injected molar
amount of peptide was significantly increased compared to the peptide amount injected
with 68Ga-NODAGA-NOC and, as a result, the binding sites in the tumor tissue may
have been saturated.
An overview of the PET/CT scans of all four peptides labeled with 44Sc at 5 h after
injection showed largely the same tissue distribution as was found at 3 h after injection
(Fig. 7). While RGD-based peptides accumulated in the U87MG tumor xenografts and
showed residual activity in the intestinal tract, NOC-based peptides accumulated in
AR42J tumors xenografts and showed significant retention of radioactivity in the
kidneys.
Discussion
A number of preclinical studies demonstrated the potential of 44Sc as an alternative
PET radiometal to the currently-used 68Ga (Müller et al. 2013; Koumarianou et al.
2012; Hernandez et al. 2014; Miederer et al. 2011). With this in mind, the possibility to
extend its applications to peptides of clinical relevance is of great interest for medical
physicians. Herein, we reported on the first, to our knowledge, preclinical studyTable 3 Tumor-to-background ratios at different time points after injection of 44Sc/68Ga-labeled
DOTA-NOC and NODAGA-NOC
44Sc-DOTA-NOC 68Ga-DOTA-NOC
AR42J 30 min p.i. 2 h p.i. 5 h p.i. 30 min p.i. 2 h p.i.
Tumor-to-blood 3.69 ± 1.52 58.2 ± 6.64 52.0 ± 4.38 5.22 ± 1.07 46.2 ± 2.28
Tumor-to-liver 6.87 ± 2.38 13.1 ± 2.16 15.7 ± 2.82 2.44 ± 0.36 2.22 ± 0.22
Tumor-to-kidney 0.79 ± 0.19 1.01 ± 0.06 0.85 ± 0.04 1.20 ± 0.21 1.41 ± 0.18
44Sc-NODAGA-NOC 68Ga-NODAGA-NOC
AR42J 30 min p.i. 2 h p.i. 5 h p.i. 30 min p.i. 2 h p.i.
Tumor-to-blood 5.23 ± 0.22 50.3 ± 16.8 78.6 ± 6.95 4.32 ± 0.58 76.0 ± 4.31
Tumor-to-liver 8.13 ± 0.72 11.9 ± 3.26 11.6 ± 1.51 4.36 ± 0.91 5.88 ± 0.68
Tumor-to-kidney 0.80 ± 0.10 1.22 ± 0.34 0.87 ± 0.24 0.58 ± 0.10 0.85 ± 0.08
Fig. 5 PET/CT scans of U87MG tumor-bearing mice 3 h after injection of ~10 MBq (~1 nmol) 44Sc-DOTA-
RGD (a), (~10 MBq/~1 nmol) 68Ga-DOTA-RGD (b), ~10 MBq (~1 nmol) 44Sc-NODAGA-RGD (c) and ~10 MBq
(~1 nmol) 68Ga-NODAGA-RGD (d). During the PET (20 min) and the CT (1.5 min) scans the mice were anes-
thetized with isoflurane/oxygen (Tu = U87MG tumor xenografts, Li = liver, Int = intestines,
Bl = urinary bladder)
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in vitro and in vivo behavior. Several authors proposed the DOTA-chelator as the most
suitable ligand for binding Sc(III), whereas for Ga(III) it is known that NODAGA com-
plexes provide higher thermodynamic stability than the DOTA complex (Huclier-Markai
et al. 2011; Notni et al. 2012). Currently, the 68Ga-DOTA functionalized somatostatin
receptor analogues are among the most prominent radiopharmaceuticals for clinical PET
imaging (Banerjee & Pomper 2013). Since NODAGA derivatized biomolecules have not
been used for labeling with 44Sc to date, the question arose on whether or not sufficient
stability can be achieved for in vivo application of 44Sc-NODAGA compounds.
In order to perform the preclinical experiments effectively, it was necessary to obtain
the 44Sc in a small solution volume, suitable for direct radiolabeling and subsequent
in vivo application, without extensive dilution. Previously, we reported on the
Fig. 6 PET/CT scans of AR42J tumor-bearing mice 3 h after injection of ~10 MBq (~1 nmol) 44Sc-DOTA-NOC
(a), ~10 MBq (~1 nmol) 68Ga-DOTA-NOC (b), ~10 MBq (~3 nmol) 44Sc-NODAGA-NOC (c) and ~10 MBq (~1 nmol)
68Ga-NODAGA-NOC (d). During the PET (20 min) and the CT (1.5 min) scans the mice were anesthetized with
isoflurane/oxygen (Tu = U87MG tumor xenografts, Li = liver, Int = intestines, Bl = urinary bladder)
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(van der Meulen et al. 2015). Although the use of this resin is already established for
the concentration of the 68Ga eluate from the 68Ge generator, the high osmolarity of
the eluate is not suitable for direct in vivo application. Herein, we report the use of
DGA extraction chromatographic resin to effectively concentrate ~85 % of the 44Sc
radioactivity in a small volume of 700 μL. The acidic solution containing the 44Sc was
mixed with sodium acetate to obtain a pH of 4–4.5 for radiolabeling reactions. This
procedure allowed in vivo application of the radiolabeled peptides without excessive
dilution.
Reproducible labeling with 44Sc at high specific activities (10 MBq/nmol) was achieved
for peptides functionalized with a DOTA-chelator. The same was possible for 68Ga with
both DOTA- and NODAGA-functionalized peptides. Radiolabeling of NODAGA-
compounds with 44Sc, however, proved to be more challenging and was not achieved
Fig. 7 PET/CT scans of U87MG tumor-bearing mice 5 h after injection of ~10 MBq (~1 nmol) 44Sc-DOTA-RGD
(a) and ~10 MBq (~1 nmol) 44Sc-NODAGA-RGD (b). PET/CT scans of AR42J tumor-bearing mice 5 h after
injection of ~10 MBq (~1 nmol) 44Sc-DOTA-NOC (c) and ~10 MBq (~3 nmol) 44Sc-NODAGA-NOC (d). During
the PET (20 min) and the CT (1.5 min) scans the mice were anesthetized with isoflurane/oxygen (Tu = U87MG
(a/b) or AR42J tumor xenografts (c/d), Ki = kidney, Int = intestines, Bl = urinary bladder)
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contaminations to which NOTA/NODAGA is more susceptible than DOTA, as previ-
ously reported (Simecek et al. 2013). If NODAGA-functionalized peptides should be used
with 44Sc for clinical studies, it will be important to determine the maximum concentra-
tion of metal contaminants which would still allow high specific and reproducible labeling
with 44Sc. A potential optimization of the labeling may also be accessible by thorough inves-
tigation of different buffer systems and the use of microwave heating (Elander et al. 2000).
Finally, even when the labeling was achieved successfully, the stability of 44Sc-labeled
NODAGA-peptides was clearly inferior to the stability of 44Sc-labeled DOTA-
compounds. It will be important, thus, to investigate the conditions which enhance the
stability of 44Sc-NODAGA-peptides, potentially allowing an increased shelf-life which
would be necessary in view of a clinical application.
In the initial in vitro test, the stability of 44Sc- and 68Ga-labeled peptides was investi-
gated in saline with and without addition of excess and Fe3+ and Cu2+, respectively, to de-
termine the possibility of metal challenge. None of the conditions impaired the integrity
of 44Sc-labeled DOTA-RGD and DOTA-NOC, even after four half-lives of incubation at
37 °C. The obtained results are in agreement with those of Pruszynski et al., who reported
an unchanged stability of 44Sc-DOTA-TOC in the presence of metal cations (Pruszynski
et al. 2012). The amount of intact 68Ga-DOTA-RGD and 68Ga-DOTA-NOC was only
decreased after the addition of Cu2+ (0.01 M) which was comparable with the time- and
Cu2+-concentration dependent transmetalation of 68Ga-DOTA-TATE (Oehlke et al.
2013). 44Sc-labeled NODAGA-peptides were significantly less stable, indicating an onset
of release of the radionuclide from the chelator only one half-life after labeling. This was
in clear contrast to the 68Ga-NODAGA-peptides, which were completely stable over the
whole period of investigation. The NODAGA-chelator revealed less stable coordination of
44Sc compared to the DOTA under the experimental conditions in this work. Distribution
coefficients determined in n-octanol and PBS pH 7.4 revealed logD values in the same
range (−4.70 to −4.26) for all RGD-based peptides, irrespective of the chelator and radio-
nuclide which was employed. The logD values obtained with NOC-based peptides
were slightly higher (−1.68 to −2.54) for all four radiopeptides (44Sc/68Ga-DOTA/
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peptides (Additional file 1: Table S1).
Biodistribution studies were performed with tumor-bearing mice at different time
points after administration of the 44Sc-labeled peptides. Application of 44Sc-DOTA/
NODAGA-RGD and 44Sc-DOTA/NODAGA-NOC, respectively, resulted in only small
variations of the kinetics, independent of whether a DOTA or a NODAGA chelator
was used (Fig. 3b). Comparing the tissue distribution profiles of 44Sc-labeled peptides
with those of 68Ga-labeled peptides revealed that the differences between DOTA- and
NODAGA-derivatized compounds were largely due to the different properties of these
peptides, rather than the consequence of any kind of instability (Fig. 4). Indications of
in vivo instability of the 44Sc-NODAGA-compounds were not apparent, with the excep-
tion of the increasing kidney uptake from 3 to 5 h after injection of 44Sc-NODAGA-NOC
(Fig. 3b). It remained unclear, however, whether this was due to release of 44Sc from the
NODAGA chelator since injection of free 44Sc resulted in unspecific retention of radio-
activity in the liver and intestinal tract, rather than in the kidneys (Additional file 1: Figure
S1). Generally, the instability of 44Sc-NODAGA compounds in solution was time-
dependent and, as a consequence, it appeared not to be an issue for imaging purposes at
relatively short time points (<1 half-life of 44Sc) after injection. The tissue distribution pro-
files with each peptide were similar, independent of whether it was labeled with 44Sc or
68Ga. One of the most conspicuous differences between 44Sc- and 68Ga-labeled peptides,
however, was the increased liver uptake of 68Ga-DOTA-peptides, which was seen in PET
images obtained with both DOTA-RGD and DOTA-NOC, respectively. Biodistribution
studies confirmed these differences in liver uptake for DOTA-NOC (Fig. 4c), however, in
the case of DOTA-RGD the liver uptake was relatively high for both 68Ga-DOTA-RGD
and 44Sc-DOTA-RGD (Fig. 4a). This was in contrast to 44Sc- and 68Ga-labeled
NODAGA-RGD peptides, which showed a clearly reduced liver uptake at 2 h p.i. in com-
parison (Fig. 4b). Since uncoordinated 68Ga may also accumulate to a significant extent in
the bones as it was shown in a separate experiment (Additional file 1: Figure S1), it is un-
likely that the described results are a consequence of released 68Ga from the DOTA-
chelator.
Previously, it was reported that 68Ga-DOTA-RGD showed a higher blood pool activity
than 68Ga-NODAGA-RGD (Knetsch et al. 2011; Decristoforo et al. 2008). As a result and
in agreement with our studies, it was found that 68Ga-DOTA-RGD accumulates to a higher
extent in the liver than 68Ga-NODAGA-RGD (Fig. 4a/b). In this context, it is also import-
ant to note that the peptide structure of the DOTA-RGD comprises a phenylalanine,
whereas in the case of the NODAGA-RGD the phenylalanine was replaced with a tyrosine,
which may have an influence on the pharmacokinetics of these peptides (Fig. 1).
Overall, 68Ga-NODAGA-RGD revealed a more favorable tissue distribution profile
than 68Ga-DOTA-RGD, shown in previous studies as well as in the experiments
presented in this work (Knetsch et al. 2011; Pohle et al. 2012). A similar trend,
albeit less pronounced, was seen for the 44Sc-labeled RGD peptides, showing lower
background activity of 44Sc-NODAGA-RGD compared to that of 44Sc-DOTA-RGD
(Fig. 4a/b).
The most striking difference between 44Sc- and 68Ga-labeled NOC-based peptides
was the reduced liver uptake of 44Sc-DOTA-NOC as compared to 68Ga-DOTA-NOC,
although 68Ga-DOTA-NOC accumulated to a higher extent in the tumor tissue than
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and 68Ga-NODAGA-NOC peptides, they were found to be largely comparable with
slightly higher retention of 68Ga-NODAGA-NOC in the kidneys (Fig. 4d). These results
were also largely comparable to previously published data obtained with 68Ga-
NODAGA-TOC (Eisenwiener et al. 2002). Even though the 44Sc-NODAGA-NOC
revealed to be the least stable in vitro, its tissue distribution profile was largely compar-
able to 68Ga-labeled NODAGA-NOC indicating that the compound was stable in vivo.
Overall, it was found that 44Sc-DOTA-peptides were of significantly higher stability
than the corresponding 44Sc-NODAGA-peptides, as expected, based on stability constants
previously reported (Huclier-Markai et al. 2011; Port et al. 2008). Our experience also
revealed that metal impurities would clearly interfere more distinctly with the stability of
44Sc-NODAGA-compounds than in the case of 44Sc-DOTA-compounds. Finally, it is
important to note that the 44Sc-labeling of a NODAGA-functionalized biomolecule ap-
pears to be dependent on the overall chemical structure of the compound, as the 44Sc-
NODAGA-RGD was found to be clearly more stable than the 44Sc-NODAGA-NOC.
NODAGA-chelators are, thus, not excluded from use for labeling with 44Sc, but a thorough
investigation of each case will be necessary in order to guarantee sufficient stability of the
radiopharmaceutical.
Based on our results, which show clear differences in kinetics between labeled
DOTA- and NODAGA-functionalized peptides, it is likely that 44Sc would be the pre-
ferred nuclide to be used with DOTA-functionalized biomolecules, in order to reflect
the tissue distribution of 177Lu-labeled compounds more accurately, than if 68Ga was
used for the same purpose.
Conclusions
In this work, it was demonstrated that 44Sc can be used for the labeling of biomolecules
with both a DOTA and NODAGA chelator, although using a NODAGA-chelator
proved to be more challenging. Other than with 68Ga, which shows clearly better
results if coordinated with a NODAGA-chelator, 44Sc appears to be more stably
complexed with DOTA. Based on these results, we conclude that even though 44Sc
would be most favorably coordinated with a DOTA-chelator, coordination with a
NODAGA-chelator is possible if the labeling conditions and storage buffers are
validated. When using 44Sc and 47Sc for theragnostic application, however, DOTA is
clearly the chelator of choice.
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